tradmap

BRTX Earnings BioRestorative Therapies, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$5 -$3 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $200500 $401000 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$44M -$22M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$4 -$2 $0 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25
EPS
Revenue (quarterly)
$0 $151650 $303300 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25
Revenue
Net income (quarterly)
-$6M -$470569 $5M $0 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25
Net income

Reported EPS history

1–18 of 18
Q1 20262026-03-31-0.122026-05-1410-Q
FY 20252025-12-31-1.582026-03-2610-K
Q3 20252025-09-30-1.262025-11-1210-Q
Q2 20252025-06-30-0.942025-08-1210-Q
Q1 20262025-03-31-0.642026-05-1410-Q
FY 20252024-12-31-1.162026-03-2610-K
Q3 20252024-09-30-0.962025-11-1210-Q
Q2 20252024-06-30-0.842025-08-1210-Q
Q1 20252024-03-31-0.332025-05-1410-Q
FY 20242023-12-31-2.472025-03-2810-K
Q3 20242023-09-30-2.002024-11-1210-Q
Q2 20242023-06-30-3.392024-08-1310-Q
Q1 20242023-03-31-1.932024-06-1110-Q
FY 20232022-12-31-5.112024-04-0110-K
Q3 20232022-09-30-3.932023-11-1310-Q
Q2 20232022-06-30-2.652023-08-1110-Q
Q2 20202020-06-300.002021-04-1210-Q
Q2 20202019-06-30-0.522021-04-1210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.